

# Anuhya Kommalapati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11409425/publications.pdf>

Version: 2024-02-01

16  
papers

517  
citations

933447

10  
h-index

996975

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

807  
citing authors

#	ARTICLE	IF	CITATIONS
1	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. <i>Cancers</i> , 2021, 13, 2968.	3.7	63
2	Association between facility volume and mortality of patients with classic Hodgkin lymphoma. <i>Cancer</i> , 2020, 126, 757-764.	4.1	5
3	Second-line therapies in advanced biliary tract cancers. <i>Lancet Oncology</i> , The, 2020, 21, e29-e41.	10.7	77
4	Prevention and treatment of FGFR inhibitor-associated toxicities. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103091.	4.4	35
5	Personalized Medicine in Advanced Cholangiocarcinoma. <i>Oncology &amp; Hematology Review</i> , 2020, 16, 52.	0.2	1
6	Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 553-555.	1.3	12
7	FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2019, 78, 1-7.	7.7	57
8	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 441-446.	0.4	9
9	Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 365-369.	3.6	88
10	Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. <i>Blood</i> , 2018, 131, 265-268.	1.4	73
11	Novel targeted treatment options for advanced cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 709-720.	4.1	42
12	Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. <i>Translational Cancer Research</i> , 2018, 7, S81-S84.	1.0	3
13	Evaluation and management of skeletal disease in cancer care. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 217-226.	4.4	12
14	Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 160.	2.8	11
15	Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. <i>Cureus</i> , 2017, 9, e1300.	0.5	29
16	Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. , 2017, 3, 5-6.		0